Athira Pharma, Inc. (NASDAQ:LONA) Receives Average Recommendation of “Hold” from Analysts

Athira Pharma, Inc. (NASDAQ:LONA) has received an average rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $15.00.

Several analysts have commented on the stock. Wall Street Zen upgraded shares of Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Piper Sandler assumed coverage on shares of Athira Pharma in a report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Athira Pharma in a report on Monday, May 11th.

Athira Pharma Stock Up 8.2%

Shares of NASDAQ:LONA opened at $9.40 on Friday. The firm has a market cap of $88.27 million, a P/E ratio of -1.80 and a beta of 1.97. The company has a 50 day moving average price of $9.16. Athira Pharma has a fifty-two week low of $2.85 and a fifty-two week high of $14.21.

Athira Pharma (NASDAQ:LONA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.73) earnings per share for the quarter. On average, equities analysts anticipate that Athira Pharma will post -3.12 earnings per share for the current year.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.